Preparing for Off the Shelf: Accelerating Allogeneic iPSC Therapies
Wednesday, May 29, 2024 01:00 PM - 02:00 PM
Room 202-204
Roundtable
Organized by: ISCT Emerging Regenerative Medicine Technology Working Group
Supported by: Astellas
Moderator
Integrate technologies for the large-scale manufacturing of iPSCs that do not elicit immune responses.
Key Learning Objectives
1. Potential clinical indication being treated with iPSC
2. How to genetically modify iPSC to use an allogenic source in several clinical indications.
3. Discuss the specifics of scale up/out, supply chain, regulatory and automation to accelerate allogenic iPSC as a biotherapeutic
Supported by: Astellas
Moderator
- Uma Lakshmipathy, PhD, Thermo Fisher Scientific, United States
- Jeanne Loring, PhD, Scripps Research, United States
- Ricardo Baptista, PhD, Biotechnology and Biochemical Engineering, SmartCella Holding, Stockholm, Sweden
- Shannon Eaker, PhD, CTO, Xcell Biosciences
- Erin Kimbrel, PhD, Astellas Institute for Regenerative Medicine (AIRM), United States
Integrate technologies for the large-scale manufacturing of iPSCs that do not elicit immune responses.
Key Learning Objectives
1. Potential clinical indication being treated with iPSC
2. How to genetically modify iPSC to use an allogenic source in several clinical indications.
3. Discuss the specifics of scale up/out, supply chain, regulatory and automation to accelerate allogenic iPSC as a biotherapeutic
SPONSORED BY:
Uma Lakshmipathy
Senior Director R&D, Site Head Patheon Translational Services
Thermo Fisher Scientific
Moderator
Senior Director R&D, Site Head Patheon Translational Services
Thermo Fisher Scientific
Moderator
